Welcome to our dedicated page for Applied Therapeutics news (Ticker: $APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied Therapeutics's position in the market.
Applied Therapeutics, Inc. reported financial results for the first quarter of 2024, highlighting significant regulatory progress regarding the potential approval of govorestat for Classic Galactosemia in the US and EU. The Company also discussed a potential NDA submission for SORD Deficiency. Dale Hooks was appointed as Chief Commercial Officer, and full results from the Phase 3 ARISE-HF Study of AT-001 in Diabetic Cardiomyopathy were presented. Financially, the Company ended the quarter with $146.5 million in cash and cash equivalents, with a net loss of $83.9 million. The Company expects its cash to fund operations into 2026.
Applied Therapeutics, Inc. (Nasdaq: APLT) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The company is a clinical-stage biopharmaceutical developing drug candidates for unmet medical needs.